Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EBITDA (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EBITDA for 16 consecutive years, with -$848305.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 33.15% to -$848305.0 in Q3 2025 year-over-year; TTM through Jul 2025 was -$4.0 million, a 551.47% decrease, with the full-year FY2025 number at -$4.4 million, down 6346.06% from a year prior.
  • EBITDA was -$848305.0 for Q3 2025 at PharmaCyte Biotech, up from -$1.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $5.4 million in Q2 2024 to a low of -$2.3 million in Q4 2022.
  • A 5-year average of -$936598.7 and a median of -$1.0 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 130.74% in 2022, then soared 700.46% in 2024.
  • PharmaCyte Biotech's EBITDA stood at -$1.0 million in 2021, then crashed by 130.74% to -$2.3 million in 2022, then soared by 39.21% to -$1.4 million in 2023, then increased by 21.53% to -$1.1 million in 2024, then grew by 23.3% to -$848305.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's EBITDA are -$848305.0 (Q3 2025), -$1.0 million (Q2 2025), and -$960252.0 (Q1 2025).